Titterton Lewis H jr 4

What Happened

• Titterton Lewis H Jr, a director of Anixa Biosciences, purchased 2,836 shares in an open-market transaction on June 16, 2026.
• The shares were acquired at $2.64 each, for a total cash outlay of about $7,487. This was a purchase (a net acquisition), which some investors view as a mild bullish signal but the amount is modest.

Key Details

• Transaction date and price: 2026-06-16 — 2,836 shares at $2.64 per share (Transaction code: P = Purchase).
• Total value: ~$7,487.
• Shares owned after transaction: not specified in the details provided.
• Footnotes/plan info: no 10b5-1 plan, tax-withholding, or other footnotes were provided in the summary.
• Filing: Form 4 was filed on 2026-06-17 (one day after the trade), which appears to be timely under Form 4 reporting rules.

Context

• Small open-market purchases like this are factual disclosures of insider buying but are modest in size and do not, by themselves, prove a change in company prospects. Retail investors may note the purchase as a positive signal from a director, but should consider it alongside other fundamentals and insider activity.